TNM classification and the need for revision of pN3a breast cancer

Abstract Background According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether progn...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer (1990) 2017-07, Vol.79, p.23-30
Hauptverfasser: van Nijnatten, T.J.A, Moossdorff, M, de Munck, L, Goorts, B, Vane, M.L.G, Keymeulen, K.B.M.I, Beets-Tan, R.G.H, Lobbes, M.B.I, Smidt, M.L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 30
container_issue
container_start_page 23
container_title European journal of cancer (1990)
container_volume 79
creator van Nijnatten, T.J.A
Moossdorff, M
de Munck, L
Goorts, B
Vane, M.L.G
Keymeulen, K.B.M.I
Beets-Tan, R.G.H
Lobbes, M.B.I
Smidt, M.L
description Abstract Background According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether prognosis of pN3a based on at least an infraclavicular LNM differs from ≥10 axillary LNMs. Methods Data were obtained from the Netherlands Cancer Registry. All patients were diagnosed between 2005 and 2008 with primary invasive epithelial breast cancer and pN2a or pN3a status as pathologic result. Patients with pN3a were subdivided in pN3a based on at least an infraclavicular LNM or ≥10 axillary LNMs. Disease-free survival (DFS) included any local, regional or contralateral recurrence, distant metastasis or death within 5 years. Kaplan–Meier curves provided information on 5-year DFS and 8-year overall survival (OS). In addition, Cox proportional hazards model was used to measure the effect of relevant clinicopathological variables on DFS and OS. Results A total of 3400 patients with pN2a and 1788 patients with pN3a were included. In 83 patients, pN3a was based on at least an infraclavicular LNM (4.6%) and in 1705 patients because of ≥10 axillary LNMs (95.4%). After multivariable analyses, DFS and OS were inferior in patients with pN3a based on ≥10 axillary LNMs compared to infraclavicular LNM (DFS 48.8% versus 63.8%, hazard ratio [HR] 1.59, p = 0.036; OS 46.6% versus 63.9%, HR 1.46, p = 0.042). Furthermore, pN2a and pN3a based on infraclavicular LNM had comparable DFS and OS. Conclusion PN3a status based on an at least an infraclavicular LNM is rare, yet its prognosis is superior to ≥10 axillary LNMs. Reclassification of infraclavicular LNM in the next TNM should therefore be considered into pN2a.
doi_str_mv 10.1016/j.ejca.2017.04.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1893971778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804917308791</els_id><sourcerecordid>1893971778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-f1e3874aa9cd2e61fa6fbb7e63bbd26726b8fb6ed2d0bd950022b0f024c78ca63</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EotvCH-CAInHhkjD-2NiWEFKpKCCVcqCcLX-MhUM2Wexspf57HG3poQdOPvh5RzPPS8grCh0F2r8bOhy87RhQ2YHoANgTsqFK6hbUlj0lG9Bb3SoQ-oScljIAgFQCnpMTpsRWUao35OPN9bfGj7aUFJO3S5qnxk6hWX5hMyGGJs65yXibyvozx2Z_zW3jMtqyNN5OHvML8izaseDL-_eM_Lz8dHPxpb36_vnrxflV6wXXSxspciWFtdoHhj2Nto_OSey5c4H1kvVORddjYAFc0Nt6DnMQgQkvlbc9PyNvj3P3ef5zwLKYXSoex9FOOB-KoUpzLamUqqJvHqHDfMhT3c4w4Ez0XFNaKXakfJ5LyRjNPqedzXeGglkNm8Gshs1q2IAwdaUaen0_-uB2GB4i_5RW4P0RwOriNmE2xSesokLK6BcT5vT_-R8exf2YplrN-BvvsDzcQU1hBsyPteO1Yio51Oop_wuHvZ-p</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2032463911</pqid></control><display><type>article</type><title>TNM classification and the need for revision of pN3a breast cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>van Nijnatten, T.J.A ; Moossdorff, M ; de Munck, L ; Goorts, B ; Vane, M.L.G ; Keymeulen, K.B.M.I ; Beets-Tan, R.G.H ; Lobbes, M.B.I ; Smidt, M.L</creator><creatorcontrib>van Nijnatten, T.J.A ; Moossdorff, M ; de Munck, L ; Goorts, B ; Vane, M.L.G ; Keymeulen, K.B.M.I ; Beets-Tan, R.G.H ; Lobbes, M.B.I ; Smidt, M.L</creatorcontrib><description>Abstract Background According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether prognosis of pN3a based on at least an infraclavicular LNM differs from ≥10 axillary LNMs. Methods Data were obtained from the Netherlands Cancer Registry. All patients were diagnosed between 2005 and 2008 with primary invasive epithelial breast cancer and pN2a or pN3a status as pathologic result. Patients with pN3a were subdivided in pN3a based on at least an infraclavicular LNM or ≥10 axillary LNMs. Disease-free survival (DFS) included any local, regional or contralateral recurrence, distant metastasis or death within 5 years. Kaplan–Meier curves provided information on 5-year DFS and 8-year overall survival (OS). In addition, Cox proportional hazards model was used to measure the effect of relevant clinicopathological variables on DFS and OS. Results A total of 3400 patients with pN2a and 1788 patients with pN3a were included. In 83 patients, pN3a was based on at least an infraclavicular LNM (4.6%) and in 1705 patients because of ≥10 axillary LNMs (95.4%). After multivariable analyses, DFS and OS were inferior in patients with pN3a based on ≥10 axillary LNMs compared to infraclavicular LNM (DFS 48.8% versus 63.8%, hazard ratio [HR] 1.59, p = 0.036; OS 46.6% versus 63.9%, HR 1.46, p = 0.042). Furthermore, pN2a and pN3a based on infraclavicular LNM had comparable DFS and OS. Conclusion PN3a status based on an at least an infraclavicular LNM is rare, yet its prognosis is superior to ≥10 axillary LNMs. Reclassification of infraclavicular LNM in the next TNM should therefore be considered into pN2a.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2017.04.002</identifier><identifier>PMID: 28458119</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Axilla ; Breast cancer ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer ; Classification ; Clavicle ; Combined Modality Therapy - methods ; Combined Modality Therapy - mortality ; Female ; Hazards ; Hematology, Oncology and Palliative Medicine ; Humans ; Invasiveness ; Kaplan-Meier Estimate ; Lymph node ; Lymph Node Excision - methods ; Lymph Node Excision - mortality ; Lymph nodes ; Lymphatic Metastasis ; Lymphatic system ; Medical prognosis ; Metastases ; Middle Aged ; Neoplasm Staging ; Netherlands - epidemiology ; Patients ; Prognosis ; Radiotherapy, Adjuvant - methods ; Radiotherapy, Adjuvant - mortality ; Reclassification ; Statistical models ; Survival ; Tumor Burden ; Tumors ; Womens health</subject><ispartof>European journal of cancer (1990), 2017-07, Vol.79, p.23-30</ispartof><rights>Elsevier Ltd</rights><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Jul 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-f1e3874aa9cd2e61fa6fbb7e63bbd26726b8fb6ed2d0bd950022b0f024c78ca63</citedby><cites>FETCH-LOGICAL-c439t-f1e3874aa9cd2e61fa6fbb7e63bbd26726b8fb6ed2d0bd950022b0f024c78ca63</cites><orcidid>0000-0002-6431-3538</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0959804917308791$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28458119$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Nijnatten, T.J.A</creatorcontrib><creatorcontrib>Moossdorff, M</creatorcontrib><creatorcontrib>de Munck, L</creatorcontrib><creatorcontrib>Goorts, B</creatorcontrib><creatorcontrib>Vane, M.L.G</creatorcontrib><creatorcontrib>Keymeulen, K.B.M.I</creatorcontrib><creatorcontrib>Beets-Tan, R.G.H</creatorcontrib><creatorcontrib>Lobbes, M.B.I</creatorcontrib><creatorcontrib>Smidt, M.L</creatorcontrib><title>TNM classification and the need for revision of pN3a breast cancer</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Abstract Background According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether prognosis of pN3a based on at least an infraclavicular LNM differs from ≥10 axillary LNMs. Methods Data were obtained from the Netherlands Cancer Registry. All patients were diagnosed between 2005 and 2008 with primary invasive epithelial breast cancer and pN2a or pN3a status as pathologic result. Patients with pN3a were subdivided in pN3a based on at least an infraclavicular LNM or ≥10 axillary LNMs. Disease-free survival (DFS) included any local, regional or contralateral recurrence, distant metastasis or death within 5 years. Kaplan–Meier curves provided information on 5-year DFS and 8-year overall survival (OS). In addition, Cox proportional hazards model was used to measure the effect of relevant clinicopathological variables on DFS and OS. Results A total of 3400 patients with pN2a and 1788 patients with pN3a were included. In 83 patients, pN3a was based on at least an infraclavicular LNM (4.6%) and in 1705 patients because of ≥10 axillary LNMs (95.4%). After multivariable analyses, DFS and OS were inferior in patients with pN3a based on ≥10 axillary LNMs compared to infraclavicular LNM (DFS 48.8% versus 63.8%, hazard ratio [HR] 1.59, p = 0.036; OS 46.6% versus 63.9%, HR 1.46, p = 0.042). Furthermore, pN2a and pN3a based on infraclavicular LNM had comparable DFS and OS. Conclusion PN3a status based on an at least an infraclavicular LNM is rare, yet its prognosis is superior to ≥10 axillary LNMs. Reclassification of infraclavicular LNM in the next TNM should therefore be considered into pN2a.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Axilla</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer</subject><subject>Classification</subject><subject>Clavicle</subject><subject>Combined Modality Therapy - methods</subject><subject>Combined Modality Therapy - mortality</subject><subject>Female</subject><subject>Hazards</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Invasiveness</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymph node</subject><subject>Lymph Node Excision - methods</subject><subject>Lymph Node Excision - mortality</subject><subject>Lymph nodes</subject><subject>Lymphatic Metastasis</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Netherlands - epidemiology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Radiotherapy, Adjuvant - methods</subject><subject>Radiotherapy, Adjuvant - mortality</subject><subject>Reclassification</subject><subject>Statistical models</subject><subject>Survival</subject><subject>Tumor Burden</subject><subject>Tumors</subject><subject>Womens health</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EotvCH-CAInHhkjD-2NiWEFKpKCCVcqCcLX-MhUM2Wexspf57HG3poQdOPvh5RzPPS8grCh0F2r8bOhy87RhQ2YHoANgTsqFK6hbUlj0lG9Bb3SoQ-oScljIAgFQCnpMTpsRWUao35OPN9bfGj7aUFJO3S5qnxk6hWX5hMyGGJs65yXibyvozx2Z_zW3jMtqyNN5OHvML8izaseDL-_eM_Lz8dHPxpb36_vnrxflV6wXXSxspciWFtdoHhj2Nto_OSey5c4H1kvVORddjYAFc0Nt6DnMQgQkvlbc9PyNvj3P3ef5zwLKYXSoex9FOOB-KoUpzLamUqqJvHqHDfMhT3c4w4Ez0XFNaKXakfJ5LyRjNPqedzXeGglkNm8Gshs1q2IAwdaUaen0_-uB2GB4i_5RW4P0RwOriNmE2xSesokLK6BcT5vT_-R8exf2YplrN-BvvsDzcQU1hBsyPteO1Yio51Oop_wuHvZ-p</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>van Nijnatten, T.J.A</creator><creator>Moossdorff, M</creator><creator>de Munck, L</creator><creator>Goorts, B</creator><creator>Vane, M.L.G</creator><creator>Keymeulen, K.B.M.I</creator><creator>Beets-Tan, R.G.H</creator><creator>Lobbes, M.B.I</creator><creator>Smidt, M.L</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6431-3538</orcidid></search><sort><creationdate>20170701</creationdate><title>TNM classification and the need for revision of pN3a breast cancer</title><author>van Nijnatten, T.J.A ; Moossdorff, M ; de Munck, L ; Goorts, B ; Vane, M.L.G ; Keymeulen, K.B.M.I ; Beets-Tan, R.G.H ; Lobbes, M.B.I ; Smidt, M.L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-f1e3874aa9cd2e61fa6fbb7e63bbd26726b8fb6ed2d0bd950022b0f024c78ca63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Axilla</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer</topic><topic>Classification</topic><topic>Clavicle</topic><topic>Combined Modality Therapy - methods</topic><topic>Combined Modality Therapy - mortality</topic><topic>Female</topic><topic>Hazards</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Invasiveness</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymph node</topic><topic>Lymph Node Excision - methods</topic><topic>Lymph Node Excision - mortality</topic><topic>Lymph nodes</topic><topic>Lymphatic Metastasis</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Netherlands - epidemiology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Radiotherapy, Adjuvant - methods</topic><topic>Radiotherapy, Adjuvant - mortality</topic><topic>Reclassification</topic><topic>Statistical models</topic><topic>Survival</topic><topic>Tumor Burden</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Nijnatten, T.J.A</creatorcontrib><creatorcontrib>Moossdorff, M</creatorcontrib><creatorcontrib>de Munck, L</creatorcontrib><creatorcontrib>Goorts, B</creatorcontrib><creatorcontrib>Vane, M.L.G</creatorcontrib><creatorcontrib>Keymeulen, K.B.M.I</creatorcontrib><creatorcontrib>Beets-Tan, R.G.H</creatorcontrib><creatorcontrib>Lobbes, M.B.I</creatorcontrib><creatorcontrib>Smidt, M.L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Nijnatten, T.J.A</au><au>Moossdorff, M</au><au>de Munck, L</au><au>Goorts, B</au><au>Vane, M.L.G</au><au>Keymeulen, K.B.M.I</au><au>Beets-Tan, R.G.H</au><au>Lobbes, M.B.I</au><au>Smidt, M.L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TNM classification and the need for revision of pN3a breast cancer</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>79</volume><spage>23</spage><epage>30</epage><pages>23-30</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Abstract Background According to the seventh edition of tumour-node-metastasis (TNM) classification, pN3a status in breast cancer patients consists of presence of an infraclavicular lymph node metastasis (LNM) and/or presence of ≥10 axillary LNMs. The aim of this study was to determine whether prognosis of pN3a based on at least an infraclavicular LNM differs from ≥10 axillary LNMs. Methods Data were obtained from the Netherlands Cancer Registry. All patients were diagnosed between 2005 and 2008 with primary invasive epithelial breast cancer and pN2a or pN3a status as pathologic result. Patients with pN3a were subdivided in pN3a based on at least an infraclavicular LNM or ≥10 axillary LNMs. Disease-free survival (DFS) included any local, regional or contralateral recurrence, distant metastasis or death within 5 years. Kaplan–Meier curves provided information on 5-year DFS and 8-year overall survival (OS). In addition, Cox proportional hazards model was used to measure the effect of relevant clinicopathological variables on DFS and OS. Results A total of 3400 patients with pN2a and 1788 patients with pN3a were included. In 83 patients, pN3a was based on at least an infraclavicular LNM (4.6%) and in 1705 patients because of ≥10 axillary LNMs (95.4%). After multivariable analyses, DFS and OS were inferior in patients with pN3a based on ≥10 axillary LNMs compared to infraclavicular LNM (DFS 48.8% versus 63.8%, hazard ratio [HR] 1.59, p = 0.036; OS 46.6% versus 63.9%, HR 1.46, p = 0.042). Furthermore, pN2a and pN3a based on infraclavicular LNM had comparable DFS and OS. Conclusion PN3a status based on an at least an infraclavicular LNM is rare, yet its prognosis is superior to ≥10 axillary LNMs. Reclassification of infraclavicular LNM in the next TNM should therefore be considered into pN2a.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28458119</pmid><doi>10.1016/j.ejca.2017.04.002</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6431-3538</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0959-8049
ispartof European journal of cancer (1990), 2017-07, Vol.79, p.23-30
issn 0959-8049
1879-0852
language eng
recordid cdi_proquest_miscellaneous_1893971778
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Axilla
Breast cancer
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer
Classification
Clavicle
Combined Modality Therapy - methods
Combined Modality Therapy - mortality
Female
Hazards
Hematology, Oncology and Palliative Medicine
Humans
Invasiveness
Kaplan-Meier Estimate
Lymph node
Lymph Node Excision - methods
Lymph Node Excision - mortality
Lymph nodes
Lymphatic Metastasis
Lymphatic system
Medical prognosis
Metastases
Middle Aged
Neoplasm Staging
Netherlands - epidemiology
Patients
Prognosis
Radiotherapy, Adjuvant - methods
Radiotherapy, Adjuvant - mortality
Reclassification
Statistical models
Survival
Tumor Burden
Tumors
Womens health
title TNM classification and the need for revision of pN3a breast cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T01%3A53%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TNM%20classification%20and%20the%20need%20for%20revision%20of%20pN3a%20breast%20cancer&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=van%20Nijnatten,%20T.J.A&rft.date=2017-07-01&rft.volume=79&rft.spage=23&rft.epage=30&rft.pages=23-30&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2017.04.002&rft_dat=%3Cproquest_cross%3E1893971778%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2032463911&rft_id=info:pmid/28458119&rft_els_id=S0959804917308791&rfr_iscdi=true